The translation of nano-pharmaceuticals from laboratory research to clinical application requires full compliance with current Good Manufacturing Practice (cGMP) standards. Although nano-pharmaceuticals offer significant clinical, technological, and socio-economic benefits, their successful market uptake has been hindered by the lack of affordable, advanced, and accessible GMP-compliant testing and manufacturing facilities.
PHOENIX addressed this challenge by establishing a science- and regulation-based Open Innovation Test Bed (OITB) that enables a seamless, timely, and cost-efficient transfer of nano-pharmaceuticals from bench to bedside. Central to this achievement was the creation of a Single Entry Point (SEP) integrating advanced infrastructure, technologies, services, and regulatory expertise. Through this platform, SMEs, academic developers, and industry gain open and fair access to the complete nano-pharmaceutical development chain, including design, process development, characterization, testing, scale-up, GMP-compliant manufacturing, and regulatory guidance.
The specific objectives of PHOENIX were to:
• Create an open-access SEP for nano-pharmaceutical services under fair conditions.
• Establish a Pharmaceutical Quality Management System (PQMS) integrating regulatory, technical, and economic risk–benefit assessment.
• Implement a fast-track-to-GMP strategy based on intensive characterization.
• Provide a one-stop-shop environment for GMP manufacturing.
• Deploy Quality-by-Design (QbD), Safe-by-Design (SbD), and Sustainability-by-Design (Sus-b-D) concepts tailored to nano-pharmaceuticals.
• Demonstrate the OITB model through industrial demo-cases.
• Develop a sustainable business model ensuring long-term operation beyond project funding.
PHOENIX fully achieved its objectives. The PHOENIX-OITB gGmbH was established in November 2023 and is fully operational, coordinating upgraded and GMP-certified partner facilities under a unified SEP. Six partners joined as shareholders, ensuring financial sustainability. The OITB employs dedicated staff, operates under a fully implemented PQMS, and provides a transparent and structured service portfolio. Five industrial demo-cases and two pro-bono cases successfully demonstrated the technical and regulatory viability of the PHOENIX OITB, confirming its capability to support late pre-clinical and early clinical development across multiple nano-pharmaceutical platforms.
